AR099798A1 - METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT - Google Patents
METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENTInfo
- Publication number
- AR099798A1 AR099798A1 ARP150100832A ARP150100832A AR099798A1 AR 099798 A1 AR099798 A1 AR 099798A1 AR P150100832 A ARP150100832 A AR P150100832A AR P150100832 A ARP150100832 A AR P150100832A AR 099798 A1 AR099798 A1 AR 099798A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen binding
- bispecific antibodies
- certain embodiments
- present application
- antibodies
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente solicitud proporciona anticuerpos biespecíficos que se enlazan a CD3 y antígenos de tumor y métodos de uso del mismo. De acuerdo con ciertas modalidades, los anticuerpos biespecíficos de la solicitud exhiben funciones efectoras reducidas y tienen un perfil de enlace único con respecto a los receptores Fcy. Los anticuerpos biespecíficos están diseñados para inducir eficazmente la muerte de células T mediadas por las células tumorales. De acuerdo con ciertas modalidades, la presente solicitud proporciona moléculas de enlace al antígeno biespecíficos que comprenden un primer dominio de enlace al antígeno que se enlaza específicamente al CD3 humano, una segunda molécula de enlace al antígeno que se enlaza específicamente a CD20 humano, y un dominio Fc que se enlaza a receptores Fcy con un específico patrón de enlace. En ciertas modalidades, las moléculas de enlace al antígeno biespecíficos de la presente solicitud son capaces de inhibir el crecimiento de tumores de células B o de melanoma que expresan CD20. Los anticuerpos biespecíficos de la solicitud son útiles para el tratamiento de varios tipos de cáncer, así como otras enfermedades y trastornos relacionados con CD20.The present application provides bispecific antibodies that bind to CD3 and tumor antigens and methods of use thereof. According to certain embodiments, the bispecific antibodies of the application exhibit reduced effector functions and have a unique binding profile with respect to Fcy receptors. Bispecific antibodies are designed to effectively induce the death of T cells mediated by tumor cells. In accordance with certain embodiments, the present application provides bispecific antigen binding molecules that comprise a first antigen binding domain that specifically binds to human CD3, a second antigen binding molecule that specifically binds to human CD20, and a Fc domain that binds to Fcy receptors with a specific binding pattern. In certain embodiments, the bispecific antigen binding molecules of the present application are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the application are useful for the treatment of various types of cancer, as well as other diseases and disorders related to CD20.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461955663P | 2014-03-19 | 2014-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099798A1 true AR099798A1 (en) | 2016-08-17 |
Family
ID=58699943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100832A AR099798A1 (en) | 2014-03-19 | 2015-03-19 | METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR099798A1 (en) |
HR (1) | HRP20210615T1 (en) |
MA (2) | MA50374B1 (en) |
-
2015
- 2015-03-18 MA MA50374A patent/MA50374B1/en unknown
- 2015-03-18 MA MA39751A patent/MA39751B1/en unknown
- 2015-03-19 AR ARP150100832A patent/AR099798A1/en unknown
-
2021
- 2021-04-19 HR HRP20210615TT patent/HRP20210615T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20210615T1 (en) | 2021-05-28 |
MA50374A (en) | 2020-01-15 |
MA50374B1 (en) | 2021-06-30 |
MA39751B1 (en) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004410A (en) | Antibody compositions for tumor treatment. | |
CL2020003179A1 (en) | (application divisional 713-2015) anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20; and uses thereof. | |
CO2018001485A2 (en) | Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3 | |
CY1122840T1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
CY1124787T1 (en) | ANTI-GITR ANTIBODIES AND METHODS OF USING THEM | |
ECSP18043564A (en) | BI-SPECIFIC MOLECULES THAT HAVE IMMUNOREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME | |
CO2018000887A2 (en) | Bispecific antibody constructs that bind to egfrviii and cd3 | |
EA201790719A1 (en) | BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF | |
CL2017001154A1 (en) | Specific binding molecules for CD73 and uses thereof | |
AR107442A1 (en) | ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER | |
EA201790060A1 (en) | BISPECIFIC CD33- and CD3-BINDING PROTEINS | |
EA201691824A1 (en) | ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS | |
EA201791554A1 (en) | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | |
BR112016030740A2 (en) | bispecific heterodimeric bodies and their uses | |
EA201690447A1 (en) | BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE OF CONNECTING WITH gpA33 AND CD3, AND THEIR APPLICATION | |
CO7160093A2 (en) | Anti-egfr antibodies and uses thereof | |
TN2016000046A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
PH12020551689A1 (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
EA201490717A1 (en) | ANTIBODIES TO ErbB3 AND THEIR APPLICATION | |
EA201792581A1 (en) | METHODS OF APPLICATION OF BISPECIFIC CD33- and CD3-BINDING PROTEINS | |
MX2015008534A (en) | ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF. | |
CO6630177A2 (en) | Compositions and methods for the diagnosis and treatment of tumors | |
AR099798A1 (en) | METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT | |
EA202090303A2 (en) | COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS | |
AR121863A2 (en) | BIESPECIFIC CD33 AND CD3-BINDING PROTEINS |